Press Releases

Webcast
13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
Thursday, November 21, 2019 2:30 pm EST
Date Title
11/15/19
Summary ToggleT2 Biosystems to Present at the 13th Annual Canaccord Genuity Medical Technology & Diagnostics Forum Printer Friendly Version LEXINGTON, Mass. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough ,
11/12/19
Summary ToggleT2 Biosystems Reports Third Quarter 2019 Financial Highlights and Provides Corporate Update Printer Friendly Version Breakthrough quarter with CMS NTAP reimbursement and endorsement; new multi-million dollar government contract; Contract with Premier; and $1.4 million in product revenue LEXINGTON, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company,”“T2,” or “T2 Biosystems”),
11/08/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , Nov. 08, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on November 5, 2019 it issued inducement awards to four
11/07/19
Summary ToggleT2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019) Printer Friendly Version Data will focus on the first RUO assay that can detect 13 resistance genes from both gram-positive and gram-negative pathogens directly from whole blood LEXINGTON, Mass. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic
10/31/19
Summary ToggleT2 Biosystems Announces 2019 Third Quarter Financial and Operational Results Release and Conference Call Date Printer Friendly Version LEXINGTON, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it will release its 2019 third quarter financial and operational results before the
10/11/19
Summary ToggleT2 Biosystems Reports Granting of Inducement Awards Printer Friendly Version LEXINGTON, Mass. , Oct. 11, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on October 3, 2019 it issued inducement awards to two new
10/02/19
Summary ToggleT2 Biosystems to Showcase Latest Innovations at IDWeek 2019 Printer Friendly Version Company will highlight breakthrough technology that helps rapidly diagnose bloodstream infections for patients suspected of sepsis   LEXINGTON, Mass. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical
09/30/19
Summary ToggleT2 Biosystems’ T2Resistance™ Panel is Now Available as a Research Use Only (RUO) Test in the U.S. Printer Friendly Version Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections   LEXINGTON, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for
09/26/19
Summary ToggleT2 Biosystems to Present at the 2019 Cantor Global Healthcare Conference Printer Friendly Version LEXINGTON, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough , chairman and chief executive officer, and John Sprague , chief
09/25/19
Summary ToggleT2 Biosystems Enters into Distribution Agreement to Expand its Innovative Rapid Diagnostic Technologies to Puerto Rico and the U.S. Virgin Islands Printer Friendly Version LEXINGTON, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into an exclusive distribution agreement that allows the Company to